A Study to Characterize the Clinical Course of Pregnant Women and Children at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn

CompletedOBSERVATIONAL
Enrollment

17

Participants

Timeline

Start Date

January 16, 2019

Primary Completion Date

September 22, 2023

Study Completion Date

September 22, 2023

Conditions
Early Onset Severe Hemolytic Disease of the Fetus and Newborn (EOS-HDFN)Erythroblastosis, Fetal
Interventions
OTHER

No intervention

No investigational drugs will be administered as part of the study

Trial Locations (18)

2170

Liverpool Hospital, Liverpool

3000

Universitair Ziekenhuis Leuven, Leuven

3052

The Royal Women's Hospital, Parkville

10032

Columbia University Medical Center, New York

15213

UPMC, Pittsburgh

18016

Hosp. Univ. San Cecilio, Granada

35392

Justus-Liebig-Universität Gießen, Kinderherzzentrum, Giessen

45267

University of Cincinnati, Cincinnati

84132

University of Utah, Salt Lake City

97239

Oregon Health and Science University, Portland

V6H 3N1

The University of British Columbia, Vancouver

M5G1X5

Mount Sinai Hospital, Toronto

H3T 1C5

Centre Hospitalier Sainte Justine, Montreal

2333 ZA

Leiden University Medical Center, Leiden

08028

Hosp Clinic de Barcelona, Barcelona

SE-141 86

Karolinska Universitetssjukhuset Huddinge, Stockholm

B15 2TG

Queen Elizabeth Hospital, Edgbaston

WC1E 6DB

University College London Hospitals NHSFT, London

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT03755128 - A Study to Characterize the Clinical Course of Pregnant Women and Children at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn | Biotech Hunter | Biotech Hunter